COVID-19 Hits Sales Of Biogen Biosimilars Portfolio
As Firm Eyes Tecfidera US Landscape
Biogen received a bump to biosimilar earnings in the first quarter of this year, but this reversed in Q2 with fewer new patients venturing out to begin treatment on its portfolio of chronic treatment options. Management addressed the numbers, as well as Mylan’s recent victory over its Tecfidera intellectual property in the US.
You may also be interested in...
Biogen Enjoys Momentum For European Biosimilar Portfolio
Biogen’s biosimilar portfolio swung back to revenue growth in the third quarter of this year, as the US firm looks to diversify from anti-TNF products into ophthalmology and take operations global.
Samsung Bioepis Moves Eylea Biosimilar To Phase III
Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.
Mylan Blocked By US Tecfidera Injunction
Mylan is aiming to be a first mover on generic Tecfidera (dimethyl fumarate), a brand with $3.3bn of sales last year, after successfully invalidating a key US patent shielding the multiple-sclerosis treatment until 2028. However, Biogen has procured a temporary injunction for now, as it seeks to defend its position on appeal.